Nuclear Medicine Market - Global Forecast 2025-2032

Nuclear medicine is rapidly redefining clinical precision, supporting targeted diagnostics and tailored therapies across multiple healthcare specialties. Senior decision-makers seeking to future-proof operations and investments require strategic visibility as technology, regulation, and global demand rapidly evolve within the nuclear medicine market.

Market Snapshot: Global Nuclear Medicine Market

The global nuclear medicine market registered significant growth, increasing from USD 14.60 billion in 2024 to USD 16.05 billion in 2025. Forward projections suggest expansion to USD 33.87 billion by 2032, equating to an impressive CAGR of 11.08%. This momentum is being driven by increased adoption of advanced radiopharmaceuticals and next-generation imaging solutions within healthcare systems worldwide, empowering stakeholders to raise standards of clinical accuracy and operational effectiveness.

Nuclear Medicine Market: Scope & Segmentation

This research provides a granular dissection of market dynamics, allowing executives to identify emerging growth engines and prioritize resources:

• Product Type: Includes diagnostic radiopharmaceuticals (such as PET and SPECT isotopes) and therapeutic agents, featuring brachytherapy isotopes (cesium-131, iodine-125, iridium-192, palladium-103) as well as therapies utilizing alpha and beta emitters for expanded clinical impact.
• Mode of Administration: Covers intravenous injection and oral ingestion, aligning delivery options with evolving therapeutic and diagnostic needs.
• Usage: Encompasses diagnostic PET and SPECT imaging—across both analog and digital platforms—and a wide array of therapeutic nuclear medicine applications.
• Application: Addresses diverse utilization in cardiology, oncology, neurology, endocrinology, orthopedics, gastroenterology, and pulmonology, confirming the broad influence of nuclear medicine across patient care pathways.
• End Users: Spans academic and research institutes, diagnostic centers, and public and private hospitals, reflecting the market’s reach from scientific advancement to daily clinical practice.
• Key Regions: Includes the Americas (such as United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan), enabling region-specific analysis and strategic alignment for localization.
• Leading Companies: Features analysis of organizations including 3B Pharmaceuticals GmbH, Actinium Pharmaceuticals, B J Madan & Co., Bayer AG, Bracco S.p.A., BWX Technologies, Clarity Pharmaceuticals, Curium, Eli Lilly and Company, GE HealthCare, IBA, Institute of Isotopes Co., Ltd, Isotopia Molecular Imaging Ltd., Jubilant Pharma Limited, Lantheus Holdings, Medi-Radiopharma Co., Ltd., Nordion, Northstar Medical Technologies LLC, Novartis AG, Nusano, PeptiDream, Radiopharm Theranostics Limited, SHINE Technologies, Siemens Healthineers AG, Sinotau Pharmaceuticals Group, South African Nuclear Energy Corporation, State Atomic Energy Corporation Rosatom, and Thor Medical AS by Nordic Nanovector ASA.

Key Takeaways: Strategic Insights for Decision-Makers

• Advanced imaging modalities and precision-targeted radiopharmaceuticals are enabling more individualized medicine, delivering measurable improvements in key disease areas such as oncology, neurology, and cardiology.
• Collaboration between academic research bodies, innovative startups, and established imaging technology firms is amplifying development of new therapeutic isotopes and expanding the utility of theranostic agents, fueling competitive differentiation.
• Ongoing enhancements in digital PET and SPECT scanners, in combination with artificial intelligence, are driving greater diagnostic certainty and fluency in clinical processes, which can streamline workflows for both providers and payers.
• Investments in robust health infrastructure, including state-of-the-art imaging equipment and integrated data platforms, are catalyzing the scale-up of nuclear medicine while helping manage costs and improve patient access.
• Market opportunities differ by geography; established economies are leveraging research to adopt new clinical applications, whereas developing regions are focusing on increasing service accessibility and bridging gaps in specialist workforce and infrastructure.

Tariff Impact on U.S. Nuclear Medicine Supply Chains

Recent adjustments in U.S. tariff policy have reshaped the economics of isotope sourcing and procurement. These changes have led domestic suppliers and manufacturers to refine purchasing strategies, prioritize domestic isotope production, and reinforce compliance across all supply chain stages to maintain operational continuity.

Methodology & Data Sources

This report incorporates findings from expert interviews, qualitative insights, and comprehensive reviews of peer-reviewed journals, clinical trial data, industry reports, financial statements, and proprietary resources. Stringent triangulation and validation methods ensure findings are precise and reliable.

Why This Report Matters

• Uncover actionable pathways for product innovation, market entry, and regulatory navigation in a highly competitive nuclear medicine landscape.
• Guide investment, capital deployment, and technology selection through validated, data-driven market intelligence tailored for executive priorities.
• Anticipate shifts in growth segments and partnership models, positioning your organization for continued leadership in an evolving healthcare ecosystem.

Conclusion

Comprehensive nuclear medicine intelligence empowers leadership teams to anticipate clinical and operational developments. This analysis equips decision-makers with the clarity and analytic foundation required for strategic growth in today’s dynamic healthcare market.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.